Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#834 Nuclear Imaging in Intermediate Grade Neuroendocrine Tumors

Introduction: Early diagnosis and grading is essential to the treatment decision-making in neuroendocrine tumors. Conventionally, proliferation rate (Ki-67) level is used for the grading of NET. Ga-68 SMS-R PET/CT is the imaging method of choice for the detection of unknown primary neuroendocrine tumors. It is very sensitive in well-differentiated tumors (Ki-67 < 2%). Poorly and undifferentiated tumors having Ki-67 greater than 20% are primarily responsible for false negativity of Ga-68 SMS-R PET/CT. In those patients, FDG-PET is performed to localize the site of the primary tumor.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Abou Yehia Z, Haydar A, Haydar M, Mukherji D, Temraz S,

Keywords: neuroendocrine tumors, nuclear imaging, histopathology ,

#310 Relationship Between Dose and Molecular Response After Peptide Receptor Radionuclide Therapy (PRRNT) in Neuroendocrine Tumors: Preliminary Results

Introduction: PRRNT is an effective therapy option in well-differentiated neuroendocrine tumors. However, there exists no study showing the ability to predict response to PRRNT on a pretherapy Ga-68 SMS-R PET/CT.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Kulkarni H, Prasad V, Schuchardt C, Baum R,

Keywords: dose, molecular, response,

#242 Ga-68 SMS-R PET/CT in the Detection of Unknown Primary Neuroendocrine Tumor- Single Centre Result in 124 Patients

Introduction: Ga-68 Somatostatin-Receptor PET/CT (R-PET/CT) has been reported to be superior to In-111 octreoscan in the detection of unknown primary of neuroendocrine tumors (CUP-NET) (EJNMMI 2010 Jan;37(1):67-77)

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Prasad V, Hommann M, Settmacher U, Kaemmerer D, Hoersch D,

Keywords: CUP NET, Ga-68 SMS-R PET/CT,

#162 Different sites of rare metastases in neuroendocrine tumor patients detected by Ga-68 somatostatin receptor PET/CT

Introduction: The most common sites of metastases in neuroendocrine tumors are liver, lymph nodes, and bone.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Prasad V, Baum R,

Keywords: neuroendocrine tumors, rare sites of metastases, Ga-68 SMS-R PET/CT,

#159 Detection of cardiac metastases in patients with neuroendocrine tumors: comparison of Ga-68 DOTA-SMS-R PET/CT, cardiac MRI, CT scan and 2D echocardiography

Introduction: Neuroendocrine tumor metastases to the heart have been sparsely reported in literature. There is as of yet no detailed study on the best imaging method for the detection of this rare site of metastases.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Prasad V, Ali S, Secknus M, Lauer B, Hoersch D,

Keywords: neuroendocrine tumors, cardiac metastases, Ga-68 SMS-R PET/CT, echocardiography, MRI,